Hjem
Universitetet i Bergen
Fan Zhous bilde

Fan Zhou

Forsker
Klinisk institutt 2
  • E-postfan.zhou@uib.no
  • Besøksadresse
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postadresse
    Postboks 7804
    5020 Bergen

Postdoctoral fellow in the Influenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway

The main focus of the Postdoc project is to study the T and B-cell immunity after influenza vaccination and/or infection in humans.

01.09.2008 - 30.06.2013

Ph.D. 

University of Chinese Academy of Sciences

Graduated from Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China

Vitenskapelig artikkel
  • Vis forfatter(e) (2024). Impact of ageing on homologous and human-coronavirus-reactive antibodies after SARS-CoV-2 vaccination or infection. npj Vaccines. 9 sider.
  • Vis forfatter(e) (2023). Vaccination prevents severe COVID-19 outcome in patients with neutralizing type 1 interferon autoantibodies. iScience. 18 sider.
  • Vis forfatter(e) (2023). SARS-CoV-2 specific immune responses in overweight and obese COVID-19 patients. Frontiers in Immunology. 11 sider.
  • Vis forfatter(e) (2023). Prolonging the delivery of influenza virus vaccine improves the quantity and quality of the induced immune responses in mice. Frontiers in Immunology.
  • Vis forfatter(e) (2023). Haemagglutination inhibition and virus microneutralisation serology assays: use of harmonised protocols and biological standards in seasonal influenza serology testing and their impact on inter-laboratory variation and assay correlation: A FLUCOP collaborative study. Frontiers in Immunology. 16 sider.
  • Vis forfatter(e) (2023). Dynamics of circulating lymphocytes responding to human experimental enterotoxigenic Escherichia coli infection. European Journal of Immunology.
  • Vis forfatter(e) (2023). Durable immune responses after BNT162b2 vaccination in home-dwelling old adults. Vaccine: X. 1-11.
  • Vis forfatter(e) (2022). Validation of a Harmonized Enzyme-Linked-Lectin-Assay (ELLA-NI) Based Neuraminidase Inhibition Assay Standard Operating Procedure (SOP) for Quantification of N1 Influenza Antibodies and the Use of a Calibrator to Improve the Reproducibility of the ELLA-NI With Reverse Genetics Viral and Recombinant Neuraminidase Antigens: A FLUCOP Collaborative Study. Frontiers in Immunology. 17 sider.
  • Vis forfatter(e) (2022). Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants. npj Vaccines. 11 sider.
  • Vis forfatter(e) (2022). The evolution of humoral immune responses to past and novel influenza virus strains gives evidence for antigenic seniority. Frontiers in Immunology. 1-15.
  • Vis forfatter(e) (2022). Symptom Burden and Immune Dynamics 6 to 18 Months Following Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2): A Case-control Study. Clinical Infectious Diseases.
  • Vis forfatter(e) (2022). Persistent Fever and Positive PCR 90 Days Post-SARS-CoV-2 Infection in a Rituximab-Treated Patient: A Case of Late Antiviral Treatment. Viruses.
  • Vis forfatter(e) (2022). Human organotypic airway and lung organoid cells of bronchiolar and alveolar differentiation are permissive to infection by influenza and SARS-CoV-2 respiratory virus. Frontiers in Cellular and Infection Microbiology. 1-23.
  • Vis forfatter(e) (2022). Durable T-cellular and humoral responses in SARS-CoV-2 hospitalized and community patients. PLOS ONE. 16 sider.
  • Vis forfatter(e) (2022). A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern. Communications Medicine. 11 sider.
  • Vis forfatter(e) (2022). A Novel Prophylaxis Strategy Using Liposomal Vaccine Adjuvant CAF09b Protects against Influenza Virus Disease. International Journal of Molecular Sciences.
  • Vis forfatter(e) (2021). Repeated Influenza Vaccination Boosts and Maintains H1N1pdm09 Neuraminidase Antibody Titers. Frontiers in Immunology. 1-11.
  • Vis forfatter(e) (2021). Matrix M Adjuvanted H5N1 Vaccine Elicits Broadly Neutralizing Antibodies and Neuraminidase Inhibiting Antibodies in Humans That Correlate With In Vivo Protection. Frontiers in Immunology. 1-13.
  • Vis forfatter(e) (2021). Long COVID in a prospective cohort of home-isolated patients. Nature Medicine. 1607-1613.
  • Vis forfatter(e) (2021). Functional and Binding H1N1pdm09-Specific Antibody Responses in Occasionally and Repeatedly Vaccinated Healthcare Workers: A Five-Year Study (2009-2014). Frontiers in Immunology.
  • Vis forfatter(e) (2021). Attack rates amongst household members of outpatients with confirmed COVID-19 in Bergen, Norway: A case-ascertained study. The Lancet Regional Health - Europe. 9 sider.
  • Vis forfatter(e) (2020). SARS-CoV-2-specific neutralizing antibody responses in Norwegian healthcare workers after the first wave of COVID-19 pandemic: a prospective cohort study. Journal of Infectious Diseases.
  • Vis forfatter(e) (2020). Live-attenuated influenza vaccine induces tonsillar follicular T helper cell responses that correlate with antibody induction. Journal of Infectious Diseases. 21-32.
  • Vis forfatter(e) (2020). Development and assessment of a pooled serum as candidate standard to measure influenza a virus group 1 hemagglutinin stalk-reactive antibodies. Vaccines. 1-18.
  • Vis forfatter(e) (2019). No evidence of antigenic seniority in hemagglutinin specific antibody responses after adjuvanted pandemic 2009 influenza vaccination. Vaccine: X. 1-8.
  • Vis forfatter(e) (2019). Functional immune response to influenza H1N1 in children and adults after live attenuated influenza virus vaccination. Scandinavian Journal of Immunology. 1-12.
  • Vis forfatter(e) (2018). T follicular-like helper cells in the peripheral blood of patients with primary Sjögren's syndrome. Scandinavian Journal of Immunology. 1-15.
  • Vis forfatter(e) (2018). Augmented CD4+ T-cell and humoral responses after repeated annual influenza vaccination with the same vaccine component A/H1N1pdm09 over 5 years. npj Vaccines. 10 sider.
  • Vis forfatter(e) (2018). Antibody responses to influenza A/H1N1pdm09 virus after pandemic and seasonal influenza vaccination in healthcare workers: A 5-year follow-up study. Clinical Infectious Diseases. 382-392.
  • Vis forfatter(e) (2017). Influenza A haemagglutinin specific IgG responses in children and adults after seasonal trivalent live attenuated influenza vaccination. Vaccine. 5666-5673.
  • Vis forfatter(e) (2017). Boosting of cross-reactive and protection-associated T cells in children after live attenuated influenza vaccination. Journal of Infectious Diseases. 1527-1535.
  • Vis forfatter(e) (2017). A DNA vaccine that targets hemagglutinin to antigen-presenting cells protects mice against H7 influenza. Journal of Virology. 1-13.
  • Vis forfatter(e) (2016). Long-term maintenance of the influenza-specific cross-reactive memory CD4+ T-cell responses following repeated annual influenza vaccination. Journal of Infectious Diseases. 740-749.
  • Vis forfatter(e) (2015). Single dose vaccination of the ASO3-adjuvanted A (H1N1)pdm09 monovalent vaccine in health care workers elicits homologous and cross-reactive cellular and humoral responses to H1N1 strains. Human Vaccines & Immunotherapeutics. 1654-1662.
  • Vis forfatter(e) (2015). Induction of local secretory IgA and multifunctional CD4+ T-helper cells following intranasal immunization with a H5N1 whole inactivated influenza virus vaccine in BALB/c mice. Scandinavian Journal of Immunology. 305-317.
Vitenskapelig foredrag
  • Vis forfatter(e) (2019). Comprehensive characterization and kinetics of circulating lymphocytes in human volunteers experimentally infected with enterotoxigenic Escherichia coli.
  • Vis forfatter(e) (2015). Cellular immune responses after live attenuated influenza vaccination in children, a clinical trial.
Brev til redaktøren
  • Vis forfatter(e) (2023). SARS-CoV-2 infection induces long-lived B and T-cell responses up to 15 months post-infection, irrespective of disease severity. Journal of Infection. 346-349.
Poster
  • Vis forfatter(e) (2019). Neuraminidase antibody responses after pandemic and seasonal influenza vaccinations: a five-year study.
  • Vis forfatter(e) (2019). Neuraminidase Antibody Responses After Pandemic And Seasonal Vaccination: A Five-Year Study.
  • Vis forfatter(e) (2018). Comprehensive characterization of circulating T follicular helper cells and plasmablasts in human volunteers experimentally infected with enterotoxigenic Escherichia coli.
Errata
  • Vis forfatter(e) (2023). Author Correction: Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants (npj Vaccines, (2022), 7, 1, (174), 10.1038/s41541-022-00586-7). npj Vaccines.
  • Vis forfatter(e) (2018). Publisher Correction: Augmented CD4+ T-cell and humoral responses after repeated annual influenza vaccination with the same vaccine component A/H1N1pdm09 over 5 years. npj Vaccines.
Vitenskapelig oversiktsartikkel/review
  • Vis forfatter(e) (2018). Improving influenza vaccines: challenges to effective implementation. Current Opinion in Immunology. 88-95.
  • Vis forfatter(e) (2018). Clinical expectations for better influenza virus vaccines - perspectives from the young investigators' point of view. Vaccines. 1-16.

Se fullstendig oversikt over publikasjoner i CRIStin.

1. To characterized in-depth the de novo SARS-CoV-2 specific antibody responses and the boosting of HCoV-reactive antibodies after SARS-CoV-2 vaccination and infection.

2. To assess the magnitude and breadth of immuntiy towards the emerging highly pathogenic avian H5N1 influenza virus.

3. To study the influenza and RSV specific immune responses in vaccination and/or infected individuals.